Half of the US hydroxychloroquine supply - the drug Trump touts as a possible coronavirus treatment - has been abruptly cut off
- The US has abruptly lost 47% of its supply of hydroxychloroquine, the drug touted by the president as a potential treatment and preventive measure for COVID-19.
- Much of the drug has been produced in India, which banned exporting it.
- Despite the president's claims, there is little scientific evidence that the drug is effective for fighting the novel coronavirus. It's normally used to treat lupus, arthritis, and malaria.
- Visit Business Insider's homepage for more stories.
Hydroxychloroquine is normally used to treat and ward off the symptoms for malaria, arthritis, and lupus. Much of it is developed in India, which on Saturday banned its export, according to Bloomberg News.
India provided about 47% of the US's supply, according to data from 2019 analyzed by Bloomberg
At a press conference on Saturday, President Trump said a request to India to release shipments of the drug that had already been ordered was under "serious consideration." The outright ban was announced by India's Directorate General of Foreign Trade on April 4, although the country had already limited exports of the drug prior to the Saturday ban.
"It's a powerful drug on malaria, and there are scientific works on this. Some strong signs," Trump said Sunday, adding that the US had a stockpile of over 29 million hydroxychloroquine pills that could be used.
"What do you have to lose?" he has said repeatedly, despite the medication's potential side effects and its unproven effects on COVID-19 patients. Clinical trials are currently underway.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and member of the White House Coronavirus Tasks Force, has multiple times said the evidence on the drug is unproven despite the president's claims. It is still undergoing clinical trials for treating COVID-19.
"In terms of science, I don't think we could definitively say it works," Fauci said during an appearance on CBS's "Face the Nation" on Sunday.
When a reporter at a press briefing on Sunday asked Fauci to answer questions about the drug, the president refused to allow him to answer, moving the press conference toward a different topic.
"He answered that question 15 times," Trump said.
Erin Fox, a drug-shortage expert and the senior pharmacy director for the University of Utah's health system told Business Insider in March that a shortage of the drug could spell trouble for those who need it.
"People rely on this medication," Fox said. "They have chronic illnesses, and they really rely on this. Once you're stable on these therapies, it's not something that is easy to switch."
India's ban on exports will likely increase prices of the medication short-term and limit supply in the long run, Bloomberg reported. The ban is aimed at ensuring the country has enough access to the drug for its own citizens, according to the report.
Do you have a personal experience with the coronavirus you'd like to share? Or a tip on how your town or community is handling the pandemic? Please email firstname.lastname@example.org and tell us your story.
And get the latest coronavirus analysis and research from Business Insider Intelligence on how COVID-19 is impacting businesses.
- DBS Bank’s custom financing leads the way for companies trying to reach net-zero goals
- Republic Day 2022 – Here is a list of wishes and messages you can send to your fellow citizens
- The world's 5 richest tech tycoons — including Elon Musk, Jeff Bezos, and Bill Gates — have already lost about $85 billion this year amid a brutal market sell-off
- Brands celebrate Republic Day with patriotic fervour
- OPINION: Tax consolidation schemes is the need of the hour for India’s renewable energy sector
- Air India's new policy on pre-flight weight checks is not going well with its staff
- Anand Mahindra responds after farmer's humiliation at SUV showroom
- MakeMyTrip's founder Deep Kalra moves into a chief mentor role